Actinogen Medical (ASX:ACW) said it completed the final patient visit in a phase 2b/3 clinical trial of its Xanamem oral therapy for Alzheimer's disease, according to a Wednesday filing with the Australian bourse.
Top-line results for the trial remain on track for November, the company said.
The company's shares jumped 5% in recent Wednesday trade.